Algiax Expands AP-325 Chronic Pain Trial to Belgium and France

Algiax Pharmaceuticals has announced an expansion of its Phase 2a clinical trial for AP-325, a compound designed to alleviate chronic neuropathic pain. The study has welcomed 12 new clinical locations in Belgium and France, supplementing the already active sites in Spain and the Czech Republic. With this extension, the total number of participating sites has increased to 25.

This broadening of the clinical trial is a significant step forward in Algiax's mission to enhance pain management research and offer effective solutions for those enduring chronic neuropathic pain. The company has expressed its enthusiasm for the enrollment of the first French patients at the notable medical centers led by Prof. Pluchon and Prof. Attal.

In Belgium, Algiax has enrolled patients with chronic post-operative neuropathic pain at the facilities directed by Dr. van Boxem and Prof. Morlion. This development highlights the company's commitment to working closely with top medical professionals to deliver groundbreaking treatments.

Ingo Lehrke, Ph.D., CEO of Algiax Pharmaceuticals, has voiced his excitement regarding the study's progress and the new sites in Belgium and France. He emphasized that the inclusion of these sites will bolster the company's capacity to deliver primary efficacy results and a comprehensive safety analysis by the end of 2024.

AP-325 is a distinctive small molecule that functions as a positive allosteric modulator of the GABAA receptor in the dorsal root ganglion. This receptor is particularly responsive to targeted treatment with GABAA modulators, which enables AP-325 to reinstate spinal inhibition and alleviate pain. In preclinical trials, AP-325 has shown a dose-dependent, enduring impact on the perception of mechanical and thermal pain across various neuropathic pain models, including those for central, peripheral, and diabetic neuropathy. Additionally, it has displayed a positive safety profile, with no indications of central side effects such as drug addiction or dizziness.

Algiax Pharmaceuticals is focused on developing superior, enduring treatments for neuropathic pain, aiming to reduce the impact of this persistent condition through GABAA signaling modulation. The company's leading candidate, AP-325, is currently under investigation in Phase 2 trials and has shown promising disease-modifying capabilities in preclinical studies, as well as a favorable safety profile in initial clinical assessments. Algiax also intends to explore the therapeutic potential of GABAA modulation further, utilizing its proprietary Thioacrylamide (ThAc) derivatives to address other chronic diseases, such as diabetes.